BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

ビジネス · 2003/7/81 分で読めます

Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies; Availability

ローカル自動翻訳 · 情報源の原言語

概要

The Food and Drug Administration (FDA) is announcing the availability of summaries of the medical and clinical pharmacology reviews of pediatric studies submitted in supplements for Hycamtin (topotecan), Pulmicort (budesonide), Temodar (temozolomide), Effexor (venlafaxine), Ditropan (oxybutynin), Flonase (fluticasone), Allegra (fexofenadine), Duragesic (fentanyl), and Monopril (fosinopril). The summaries are being made available consistent with the Best Pharmaceuticals for Children Act (BPCA). For all pediatric supplements submitted under the BPCA, the BPCA requires FDA to make available to the public a summary of the medical and clinical pharmacology reviews of the pediatric studies conducted for the supplement.

情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →

関連インサイト

ビジネスインサイト →